Global /United States /Healthcare /Drug Manufacturers - General /CTOR

Citius Oncology, Inc.

CTOR

• NASDAQ: CTOR • Delayed

0.8600USD -0.8%

As of 13 June 2026, Citius Oncology, Inc. has a market cap of $75.92M USD, ranking #27515 globally and #4173 in the United States. It ranks #2477 in the Healthcare sector, and #889 in the Drug Manufacturers - General industry.

Global Rank

27515

Country Rank

4173

Sector Rank

2477

Industry Rank

889

Key Stats

Market Cap

$75.92MUSD

Enterprise Value

$70.25MUSD

Revenue (TTM)

$3.94MUSD

Net Income (TTM)

-$23.64MUSD

PS Ratio

18.7

PB Ratio

1.3

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Leonard Mazur open_in_new

Founded

2021

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-0.8%	-9.4%	59%	-25%	-53%	-19%	16%	-92%	-93%

News

CTOR Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	CTOR Citius Oncology Inc ISIN: US17331Y1091 Shares Out.: Shares Outstanding: 92.981M¹ Shares Float: 26.085M² TV: TradingView: NASDAQ: CTOR SA: Stock Analysis: NASDAQ: CTOR YF: Yahoo Finance: CTOR GF: Google Finance: NASDAQ: CTOR NQ: NASDAQ: CTOR BA: Barron's: CTOR MS: Morningstar: XNAS: CTOR	0.8600 USD	TV: TradingView: NASDAQ: CTOR SA: Stock Analysis: NASDAQ: CTOR YF: Yahoo Finance: CTOR GF: Google Finance: NASDAQ: CTOR NQ: NASDAQ: CTOR BA: Barron's: CTOR MS: Morningstar: XNAS: CTOR

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Citius Oncology, Inc.

Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidiary of Leonard-Meron Biosciences, Inc.

Similar Companies

Industry: Drug Manufacturers - General (United States)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 1M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 721K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 475K%	97.4	United States
Merck & Co., Inc. NYSE: MRK	$274.03B 361K%	15.1	United States
Pfizer Inc. NYSE: PFE	$149.38B 197K%	19.5	United States
Bristol-Myers Squibb Co. NYSE: BMY	$117.58B 155K%	16.8	United States

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Roche Holding AG SIX: RO	$321.52B 256.25B CHF 423K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.84B 215.59B GBP 380K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.65B 218.9B CHF 362K%	20.5	Switzerland
Novo Nordisk A/S CPH: NOVO-B	$181.82B 1.18T DKK 239K%	11.5	Denmark
Sanofi EPA: SAN	$110.1B 95.26B EUR 145K%	19.9	France
GSK plc LSE: GSK	$108.46B 80.96B GBP 143K%	14.6	United Kingdom

chevron_leftBack